Network Meta-Analysis of Triple Immunosuppressive Therapies and Standard of Care for Induction of Remission of Active Lupus Nephritis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0849; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Direct comparisons of SOC+Tacrolimus, SOC+Voclosporin, SOC+Belimumab, and SOC+Obinutuzumab compared to SOC alone demonstrated significantly higher remission of LN without excessive risk of serious adverse events (SAEs)...Results Patients who received SOC+Tacrolimus had significantly higher PRR compared to SOC+Rituximab (benefit ratio 2.30 [95% Credible interval 1.27-4.20]), SOC+Anifrolumab (1.98 [1.07-3.52]), SOC+Ocrelizumab (1.81 [1.12-2.82]), and SOC+Abatacept (1.78 [1.07-2.91]) (Table)...SOC+Rituximab had the lowest relative risk of SAEs. Relative benefit ratios with 95% credible intervals of the primary efficacy outcome of primary renal remission in lower triangle (column compared to row as reference) and the relative risk ratios with 95% credible intervals of the primary safety outcome of serious adverse event in upper triangle (row compared to column as reference) Φ significant difference of benefit ratios."
Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Gabriel Contreras; Vinodh Mechery; Sanjana Kota; Daniel Sebastian Del Castillo Rix; Miguel Antonio Bandes; Adriana Dejman; Yiqin Zuo; Juan Duque; Jair Munoz Mendoza
|